A case of schizophrenia with dysphagia successfully treated by a multidimensional approach.
Dysphagia in patients with psychiatric illnesses contributes to morbidities and mortalities. It is, however, an overlooked problem in clinical practice. We report a patient of schizophrenia with dysphagia who was successfully treated using a multidimensional approach, which included medication adjustment, swallowing training and diet modification.
Tang
Kuo T
KT
Department of Psychiatry, National Taiwan University Hospital, Taipei 100, Taiwan. s881122@ym.edu.tw
Hsieh
Ming H
MH
D000284:Administration, Oral; D000547:Amantadine / Q000627:therapeutic use; D018692:Antimanic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D003680:Deglutition Disorders / Q000139:chemically induced* / Q000534:rehabilitation*; D004032:Diet; D004359:Drug Therapy, Combination; D005475:Flupenthixol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D033183:Interdisciplinary Communication; D008297:Male; D008875:Middle Aged; D010348:Patient Care Team; D026741:Physical Therapy Modalities; D012559:Schizophrenia / Q000534:rehabilitation*; D013469:Sulpiride / Q000009:adverse effects* / Q000627:therapeutic use; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
D018692:Antimanic Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D014635:Valproic Acid; D013469:Sulpiride; D000547:Amantadine; D005475:Flupenthixol